Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thromboembolism.

M de Swiet

    Clinics in Haematology
    |October 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Venous thromboembolism is a significant cause of maternal mortality. Objective tests and tailored anticoagulant therapies, like heparin and warfarin, are crucial for managing this condition during and after pregnancy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    PIERS proteinuria: relationship with adverse maternal and perinatal outcome.

    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2011
    Same author

    Comparison of the arrhythmogenic effects of tauro- and glycoconjugates of cholic acid in an in vitro study of rat cardiomyocytes.

    BJOG : an international journal of obstetrics and gynaecology·2004
    Same author

    Glomerular endotheliosis in normal pregnancy and pre-eclampsia.

    BJOG : an international journal of obstetrics and gynaecology·2004
    Same author

    Assessment of adrenocortical function in women taking exogenous glucocorticoids during pregnancy.

    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2003
    Same author

    Maternal mortality, a vindication of obstetric medicine.

    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2003
    Same author

    Severe Acute Respiratory Syndrome and pregnancy.

    BJOG : an international journal of obstetrics and gynaecology·2003
    Same journal

    Myelodysplastic syndromes.

    Clinics in haematology·1986
    Same journal

    In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.

    Clinics in haematology·1986
    Same journal

    Myelodysplastic syndromes: natural history and features of prognostic importance.

    Clinics in haematology·1986
    Same journal

    Pathogenesis and clinical variations in the myelodysplastic syndromes.

    Clinics in haematology·1986
    Same journal

    The treatment of myelodysplastic syndromes.

    Clinics in haematology·1986
    Same journal

    Secondary myelodysplastic syndromes and leukaemias.

    Clinics in haematology·1986
    See all related articles

    Area of Science:

    • Obstetrics and Gynecology
    • Hematology
    • Cardiovascular Medicine

    Background:

    • Venous thromboembolism (VTE) affects approximately 0.7 per thousand maternities.
    • Pulmonary embolism is the leading cause of maternal mortality.
    • Key risk factors include operative delivery, advanced maternal age, multiparity, and prior VTE.

    Purpose of the Study:

    • To outline diagnostic and management strategies for venous thromboembolism in pregnancy.
    • To address the challenges of anticoagulant therapy and clinical diagnosis in obstetric patients.
    • To provide guidance on VTE management for specific patient groups, including those with artificial heart valves or antithrombin III deficiency.

    Main Methods:

    • Utilizing objective diagnostic tests such as venography for deep-vein thrombosis and lung scans for pulmonary embolism.

    Related Experiment Videos

  • Employing continuous heparin infusion for acute VTE, followed by subcutaneous heparin for at least six weeks postpartum.
  • Considering warfarin substitution after the first postpartum week, with specific protocols for pregnant patients with artificial heart valves.

    • Main Results:

    • Heparin therapy is standard for acute VTE, with warfarin as a potential substitute postpartum.
    • Pregnant patients with artificial heart valves require warfarin until 36 weeks gestation, despite fetal risks.
    • Current prophylactic regimens of subcutaneous heparin may be insufficient for high-risk patients with a history of VTE.

    Conclusions:

    • Objective diagnostic methods are essential for accurate VTE diagnosis in pregnancy.
    • Anticoagulant therapy requires careful consideration of maternal and fetal risks, with tailored approaches for different patient populations.
    • Further research is needed to optimize VTE prophylaxis and treatment strategies in pregnant individuals.